Search
- Dec 10, 2023
Incyte CEO Hervé Hoppenot on axatilimab for GvHD, BET inhibition, oral PD-1s and more from #ASH23
Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi.